Trevi Therapeutics, Inc.
TRVI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.84 | -1.96 | 0.89 | 0.62 |
| FCF Yield | -1.84% | -1.42% | -1.82% | -2.19% |
| EV / EBITDA | -107.96 | -48.59 | -69.94 | -35.54 |
| Quality | ||||
| ROIC | -7.28% | -6.87% | -11.41% | -12.18% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.92 | 0.82 | 1.30 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -141.25% | 25.05% | -41.02% | -0.01% |
| Safety | ||||
| Net Debt / EBITDA | 4.76 | 9.46 | 1.79 | 2.91 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -12,243.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 327.95 |